Alan DeRossettElon holds a grudge after nearly 20 years of Putin bots and fossil fuel cater calling him and Tesla owners losers stay tuned to the next episode as Elons lawyers prove Twitter has millions of bots and fake users More than it legally said in Elons contr… See more.
Steven PostrelThe incompetence of this bad cut-and-paste article is notable. The S&P 500 is not new, not ESG related, and not dropping Tesla.
There is a separate “S&P 500 ESG” product that is relatively new and that dropped Tesla, but it isn’t the benchmark that a… See more.
Those who call for mandatory reporting have the right intent, but if it’s not implemented in the right way, it will cause more harm than good.
Mandatory reporting almost always puts companies at risk, either legally or through financial penalties. Penalizing an organization for not reporting a breach in time puts it in a worse cybersecurity posture because it is a strong incentive to turn a blind eye to attacks. Alternatively, if a company knows of a breach, it will find ways to “classify” it in a way that falls into a reporting loophole.
The reporting timelines in the law are arbitrary and not based in the reality of effective incident response. The first hours and days after a breach are integral to the actual incident reporting process, but they are chaotic, and teams are sleep-deprived. Working with lawyers to determine how to report and figuring out the evidence that companies do and don’t want to “see” just makes the process harder.
Combating Antibiotic-Resistant Bacteria — Dr. Erin Duffy, Ph.D., Chief of Research & Development, and Kevin Outterson, ESQ., Executive Director, CARB-X.
The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X — https://carb-x.org/) is a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, a leading cause of death around the world. 1.27 million deaths worldwide were attributed to resistant bacterial infections in 2019.
The CARB-X portfolio is the world’s most scientifically diverse, early development pipeline of new antibiotics, vaccines, rapid diagnostics and other products and represents the only global partnership that integrates solutions for the prevention, diagnosis and treatment of life-threatening bacterial infections, translating innovation from basic research to first-in-human clinical trials.
Dr. Erin Duffy, PhD., is Chief of Research & Development at CARB-X and she has two decades of drug-discovery and problem-solving experience in the antibiotic arena. She was previously with Rib-X Pharmaceuticals (now Melinta Therapeutics) where in increasing roles she helped to build and sustain a team of researchers that translated the company’s scientific platform into next-generation and novel antibiotics that target the ribosome. Her team’s most recent achievements include the de novo design and optimization of a completely new class of antibiotics, the pyrrolocytosines, which were supported in part by CARB-X. Prior to Rib-X, Erin was the Associate Director of Innovative Discovery Technologies at Achillion Pharmaceuticals, responsible for building the structure and computational teams and platform for their antiviral efforts. She began her industrial career at Pfizer Central Research, in Groton, Connecticut, where she joined a team of computational and structural drug designers in multiple therapeutic areas. Erin was trained formally at Yale University, where she became a physical-organic chemist focused on defining computationally how small molecules interact and react in the group of Professor William L. Jorgensen. She expanded her experience to large molecules under the mentorship of Professor Axel Brunger, whose group at Yale was transitioning to a mix of computational and laboratory structural biology.
Kevin Outterson, ESQ., is Executive Director of CARB-X and is a global thought leader on business models for antibiotic development and use. He is Professor of Law and N. Neil Pike Scholar of Health and Disability Law at Boston University School of Law, where he leads multi-disciplinary teams to solve global health issues. Professor Outterson is the Executive Director and Principal Investigator of CARB-X and a partner in DRIVE-AB (aka Driving Reinvestment In Research And Development And Responsible Antibiotic Use) a project composed of 15 public and 7 private partners from 12 countries that is funded by the Innovative Medicines Initiative (IMI) joint undertaking between the European Union and the European Pharmaceutical Industry Association (EFPIA). He also leads the Social Innovation on Drug Resistance program at Boston University.
The first experimental evidence to validate a newly published universal law that provides insights into the complex energy states for liquids has been.
Sending miniature robots deep inside the human skull to treat brain disorders has long been the stuff of science fiction—but it could soon become reality, according to a California start-up.
The TechCrunch Global Affairs Project examines the increasingly intertwined relationship between the tech sector and global politics.
Geopolitical actors have always used technology to further their goals. Unlike other technologies, artificial intelligence (AI) is far more than a mere tool. We do not want to anthropomorphize AI or suggest that it has intentions of its own. It is not — yet — a moral agent. But it is fast becoming a primary determinant of our collective destiny. We believe that because of AI’s unique characteristics — and its impact on other fields, from biotechnologies to nanotechnologies — it is already threatening the foundations of global peace and security.
The rapid rate of AI technological development, paired with the breadth of new applications (the global AI market size is expected to grow more than ninefold from 2020 to 2028) means AI systems are being widely deployed without sufficient legal oversight or full consideration of their ethical impacts. This gap, often referred to as the pacing problem, has left legislatures and executive branches simply unable to cope.
How can you prove that we may not be from here? The complexity of our DNA doubles every 600M years (Moores Law) so if you take the timeline back to where it intersects when life must have begun, it would be about 9.5B years ago, but the Earth has only been around for about 4.5B years. What gives?
This video is a short 1 min 12 second clip from a great documentary by Caroline Cory, “ET Contact: They Are Here”, available on iTunes:
USPS has been criticized for not ordering more EVs.
The United States Postal Service announced its initial order of 50,000 next-generation delivery vehicles, 10,019 of which will be battery-electric vehicles. It’s a notable number considering the agency’s resistance to calls for increasing the number of EVs in its future delivery fleet.
Originally, the postal service said it would purchase 165,000 next-generation mail trucks, only 10 percent of which will be battery-electric vehicles. President Joe Biden and congressional Democrats urged the agency to increase the number of EVs, but USPS determined there was no legal reason to change its plans.
Now, the postal service says it will increase its initial order of EVs from 5,000 to 10,019, determining it “makes good sense from an operational and financial perspective.”
